导电系统加速改善了心脏功能,心肌工作和心力衰竭中的功能能力,减少了喷射分数和右捆分支块
Anna Zsófia Tóth1, László Nagy1, Csaba Jenei1
1Division of Cardiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Móricz Zsigmond krt. 22., H-4032 Debrecen, Hungary.
Journal of clinical medicine
|January 10, 2026
概括
导电系统节奏 (CSP) 在患有右束枝阻塞 (RBBB) 的心力衰竭患者中显著改善了心脏功能和运动能力. 这些发现表明,CSP对于这个患者群体来说是一个有前途的替代方案.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 心脏衰竭管理的管理
背景情况:
- 导电系统节奏 (CSP) 被探索为心力衰竭与减少喷射率 (HFrEF) 和捆绑分支阻塞的双心脏节奏 (BVP) 的替代方案.
- CSP可能在右捆支部阻塞 (RBBB) 患者中提供好处,但其对心脏力学和能量学的影响需要进一步定义.
研究的目的:
- 评估传导系统节奏 (CSP) 的心脏衰竭患者的心声心脏和临床结果,其中包括心脏衰竭患者的心脏衰竭与减少喷射分数 (HFrEF) 和右捆支部阻塞 (RBBB).
- 评估CSP对心脏力学,能量,功能状态和NT-proBNP水平在这个特定患者队列中的影响.
主要方法:
- 导电系统步调 (CSP),包括他的捆绑步调或左捆绑分支区域步调,试图作为主要策略.
- 患者有RBBB,QRS持续时间≥130毫秒,LVEF<35%,尽管医疗治疗优化,但NYHAII-IV症状.
- 心声学参数,功能状态 (NYHA类,6分钟步行距离) 和NT-proBNP水平在基线和节奏后6个月被评估.
主要成果:
- CSP减少了QRS持续时间 (155.3到130毫秒),增加了左心室喷射率 (LVEF) (27%到33%).
- 在左心室全球纵向应变,峰值应变分散,心肌工作指数,建设性工作和工作效率方面观察到显著的改善.
- 临床结果有所改善,包括NYHA类,步行6分钟的距离,以及NT-proBNP水平的下降.
结论:
- 导电系统节奏 (CSP) 在RBBB的HFrEF患者中显示出功能能力和心脏力学显著改善.
- 该研究表明,CSP是一种可行的选择,可以提高心肌工作和效率,从而有可能改善这一群体的结果.
- 通过大规模的多中心随机试验进行进一步验证是有必要的,以证实这些有希望的发现.
相关概念视频
Conduction System of the Heart
3.3K
The cardiac conduction system produces and transmits electrical impulses that prompt myocardial contraction, ensuring efficient heart function. This intricate system ensures that the heart beats in a coordinated and efficient manner, beginning with the atria and then the ventricles. The conduction system optimizes cardiac output by maintaining this precise sequence, which is crucial for adequate blood circulation.
This system relies on the unique properties of nodal and Purkinje cells:...
This system relies on the unique properties of nodal and Purkinje cells:...
3.3K
Conduction System of the Heart
12.4K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
12.4K
Pathophysiology of Heart Failure
2.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.8K
Pathophysiology of Cardiac Performance
1.3K
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.3K
Cardiomyopathy II: Dilated Cardiomyopathy
455
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
455
Heart Failure Drugs: β-Blockers
755
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
755


